Sun Pharma Advanced Research Company Ltd

SPARC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharma Advanced Research Company Ltd

₹ 204 7.44%
22 Nov - close price
sparc.life BSE: 532872 NSE: SPARC
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Leadership[1]
First listed pharma R&D company out of India where founders still own 70% and continue to invest.

Website BSE NSE
  • Market Cap ₹ 6,636 Cr.
  • Current Price ₹ 204
  • High / Low ₹ 474 / 189
  • Stock P/E
  • Book Value ₹ 3.85
  • Dividend Yield 0.00 %
  • ROCE -109 %
  • ROE -122 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 53.2 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -16.2% over past five years.
  • Company might be capitalizing the interest cost
  • Promoters have pledged 69.5% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Miscellaneous

Part of BSE 250 SmallCap Index Nifty Smallcap 250 BSE Allcap Nifty 500 BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
28 62 25 28 32 131 48 24 21 14 17 17 13
83 73 92 107 94 115 137 126 113 116 124 112 117
Operating Profit -55 -11 -67 -78 -63 16 -90 -102 -91 -103 -108 -95 -104
OPM % -196% -18% -264% -275% -198% 12% -188% -427% -432% -740% -649% -566% -808%
5 0 0 0 0 0 11 10 8 6 4 2 0
Interest 3 2 2 2 3 3 0 0 0 0 1 1 1
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 3
Profit before tax -55 -16 -71 -82 -68 10 -82 -95 -86 -100 -107 -97 -108
Tax % -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0%
-55 -16 -71 -82 -68 10 -82 -95 -86 -100 -107 -97 -108
EPS in Rs -2.09 -0.60 -2.61 -3.03 -2.52 0.37 -2.53 -2.94 -2.66 -3.07 -3.29 -2.98 -3.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
87 167 156 161 181 78 183 77 253 137 239 76 60
104 134 191 224 304 321 334 387 388 324 453 479 469
Operating Profit -17 34 -35 -63 -123 -243 -151 -310 -135 -187 -214 -404 -409
OPM % -19% 20% -23% -39% -68% -310% -83% -404% -53% -136% -90% -534% -681%
2 10 3 3 14 54 14 10 5 7 11 29 12
Interest 4 6 0 2 2 0 0 3 11 13 8 2 3
Depreciation 3 4 7 8 8 8 8 9 11 10 12 12 11
Profit before tax -22 34 -40 -70 -119 -197 -145 -312 -151 -203 -223 -388 -411
Tax % -0% 12% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0%
-22 30 -40 -70 -119 -197 -145 -312 -151 -203 -223 -388 -411
EPS in Rs -0.91 1.23 -1.60 -2.83 -4.82 -7.85 -5.55 -11.92 -5.77 -7.48 -6.86 -11.96 -12.66
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0% -0%
Compounded Sales Growth
10 Years: -8%
5 Years: -16%
3 Years: -33%
TTM: -73%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -62%
Stock Price CAGR
10 Years: 1%
5 Years: 4%
3 Years: -7%
1 Year: -25%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -122%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 24 24 24 24 25 25 26 26 26 27 32 32
Reserves 85 116 76 8 133 160 270 -45 -194 -230 480 92
81 5 4 56 3 2 2 67 236 79 16 56
20 39 39 75 111 122 101 224 162 404 302 305
Total Liabilities 209 184 143 163 273 309 398 273 230 280 830 486
66 64 67 70 69 52 58 104 91 92 106 103
CWIP 0 1 0 1 1 3 24 32 5 26 27 44
Investments 97 6 -0 -0 10 108 211 8 6 12 291 2
46 112 76 92 192 146 106 128 127 150 406 338
Total Assets 209 184 143 163 273 309 398 273 230 280 830 486

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-95 37 -41 -44 -128 -183 -172 -211 -152 -208 -69 -429
-99 44 53 -13 -7 -105 -102 155 2 -29 -548 391
194 -81 -1 51 194 224 274 55 159 229 617 43
Net Cash Flow -0 -0 11 -7 60 -63 0 -0 9 -8 -1 4

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 105 61 47 21 78 82 20 76 25 74 50 75
Inventory Days -0 -0 -0 -0 -0 -0 -0 -0 -0
Days Payable
Cash Conversion Cycle 105 61 47 21 78 82 20 76 25 74 50 75
Working Capital Days 72 129 21 -42 -59 -232 -98 -557 -96 -97 -189 -509
ROCE % -20% 21% -32% -71% -94% -143% -62% -183% -242% -106% -109%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
68.10% 69.09% 69.09% 69.09% 68.23% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68%
2.51% 2.38% 2.40% 2.38% 3.48% 3.64% 3.64% 3.67% 3.30% 3.24% 2.64% 2.15%
0.55% 0.76% 0.76% 0.76% 0.76% 0.63% 0.63% 0.65% 0.67% 0.67% 0.17% 0.21%
28.84% 27.77% 27.75% 27.77% 27.53% 30.04% 30.06% 29.99% 30.36% 30.41% 31.51% 31.96%
No. of Shareholders 95,03992,73694,49493,71896,33798,7771,00,8071,01,4331,03,9901,02,7431,25,1841,28,205

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls